OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, May 09, 2012

No One is More Interested in Curing Your Cancer Than You « Dr. Robert A. Nagourney – Rational Therapeutics – Blog



No One is More Interested in Curing Your Cancer Than You « Dr. Robert A. Nagourney – Rational Therapeutics – Blog

No One is More Interested in Curing Your Cancer Than You

A diagnosis of cancer thrusts a, heretofore, healthy individual into the strange and unfamiliar territory of medical oncology. Many of my patients describe this transition as “entering the cancer bubble.” Suddenly, you are on the inside and everyone on the outside is talking at you about what to do, where to go, whom to see, and what treatments to receive.
From the inside of the bubble however, all of this has a hollow ring as you ponder many options, few good and some, positively frightening. Unfortunately, few patients have the time to complete a MD, or PhD, between diagnosis and the initiation of treatment. Lacking the requisite expertise, they turn to the “authorities” for advice.

AHRQ Patient Safety Network - The Collection: Annotated links to patient safety literature, news, and other resources.



AHRQ Patient Safety Network - The Collection

Produced for the Agency for Healthcare Research and Quality by a team of editors at the University of California, San Francisco with guidance from a prominent Editorial Board and Advisory Panel.

again! Pet food recalled after salmonella outbreak | Healthy Living - Yahoo! Shine



Pet food recalled after salmonella outbreak | Healthy Living - Yahoo! Shine

New roles for public health in cancer screening - CA: A Cancer Journal for Clinicians



New roles for public health in cancer screening - 2012 - CA: A Cancer Journal for Clinicians

paywalled: Why should I talk about emotion? Communication patterns associated with physician discussion of patient expressions of negative emotion in hospital admission encounters



Why should I talk about emotion? Communication patterns associated with physician discussion of patient expressions of negative emotion in hospital admission encounters

Objective 
To describe hospital-based physicians’ responses to patients’ verbal expressions of negative emotion and identify patterns of further communication associated with different responses.

Practice implications 
Providers should respond to expressions of negative emotion with statements that allow for or explicitly encourage further discussion of emotion.

paywalled: What Can We Learn About the Spiritual Needs of Palliative Care Patients From the Research Literature?



What Can We Learn About the Spiritual Needs of Palliative Care Patients From the Research Literature?

Context 
Spirituality is a distinctive subject within palliative care practice and literature, but research to date is relatively undeveloped in this field and studies often throw more light on conceptual and methodological issues than producing reliable data for clinical practice.

Objectives 
To determine what is known about the spiritual needs of palliative care patients from the evidence presented in published research.

Methods 
Specialist online databases were interrogated for primary empirical studies of patients with a chronic disease unresponsive to curative treatment. Studies that only used a proxy for the patient or reported expert opinion were excluded. Each study was critically appraised for quality and the strength of its evidence to determine if any data could be pooled.

Results 
Thirty-five studies were identified, equating to a total of 1374 patients.

VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5



VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5

Objective 
To evaluate the role of VEGF-dependent Claudin 5 production for the development of ascites via influencing endothelial permeability in peritoneal tissue of ovarian cancer patients.

Conclusion 
VEGF induces ascites in ovarian cancer patients. This instance happens due to increased peritoneal permeability, caused by downregulation of the tight junction protein Claudin 5 in the peritoneal endothelium.


paywalled - Outcomes of Primary Surgical Cytoreduction in Patients with BRCA-associated High-grade Serous Ovarian Carcinoma



 Outcomes of Primary Surgical Cytoreduction in Patients with BRCA-associated High-grade Serous Ovarian Carcinoma


Objective

BRCA-associated and sporadic ovarian cancers have different pathologic and clinical features. Our goal was to determine if BRCA mutation status is an independent predictor of residual tumor volume following primary surgical cytoreduction.

Highlights

► Differences in the biology of BRCA-associated and sporadic ovarian cancers do not result in differences in primary surgical outcomes.
► The improved survival of BRCA-associated ovarian cancers is not confounded by differences in primary surgical outcome.

(in research - genome) Integrated Analysis of Gene Expression and Tumor Nuclear Image Profiles Associated with Chemotherapy Response in Serous Ovarian Carcinoma



Integrated Analysis of Gene Expression and Tumor Nuclear Image Profiles Associated with Chemotherapy Response in Serous Ovarian Carcinoma
 

Background
Small sample sizes used in previous studies result in a lack of overlap between the reported gene signatures for prediction of chemotherapy response. Although morphologic features, especially tumor nuclear morphology, are important for cancer grading, little research has been reported on quantitatively correlating cellular morphology with chemotherapy response, especially in a large data set. In this study, we have used a large population of patients to identify molecular and morphologic signatures associated with chemotherapy response in serous ovarian carcinoma.

paywalled: Increased expression of OCIA domain containing 2 during stepwise progression of ovarian mucinous tumor - Pathology Intl



Increased expression of OCIA domain containing 2 during stepwise progression of ovarian mucinous tumor

Ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) has been reported to show cancer-specific expression in early invasive lung adenocarcinoma. OCIAD2 shows high homology with OCIAD1, which was originally immunoscreened from ascites of a patient with ovarian cancer and found to be a tumor-specific protein. Therefore, like OCIAD1, OCIAD2 is expected to show high immunoreactivity in ovarian tumors.

In this study, we examined the expression pattern of OCIAD2 in 117 ovarian mucinous tumors, and confirmed that it was more highly expressed in borderline tumor and carcinoma (51/74 cases, 69%) than in adenoma (6/43 cases, 14%). The immunoreactivity of OCIAD2 in borderline tumor and carcinoma was more specific than that of OCIAD1 (adenoma, 21/43 cases, 49%), and more sensitive than that of CEA (borderline tumor and carcinoma, 35/74 cases, 47%). Like OCIAD1, OCIAD2 is a cancer-related protein and its expression level increases during the course of malignant progression and is thought to be a very useful marker for evaluating the malignancy of ovarian mucinous tumors.

Fertility Q&A Ovarian Tissue Freezing



Fertility Q&A Ovarian Tissue Freezing:

An emerging method of fertility preservation offers hope for women with cancer.

By Karine Chung, MD, MSCE

If you are preparing to undergo cancer treatment, you may already be aware that cancer therapies—including chemotherapy and radiation—can cause infertility and premature menopause. If having children after completing your cancer treatment is important to you, you may have begun to consider options for fertility preservation. Because your chance of future successful pregnancies is best when fertility preservation procedures are performed before chemotherapy or radiation, the amount of time available to pursue these procedures is often limited and depends on when your cancer treatment is scheduled to start........

Complementary Therapies in Cancer Care



Complementary Therapies in Cancer Care:

An ongoing series highlighting complementary therapies
By Barrie R. Cassileth, MS, PhD

Complementary therapies are noninvasive, nonpharmacologic adjuncts to mainstream treatment.  They improve patients’ strength and control the physical and emotional symptoms associated with cancer and other serious illnesses. They provide self-help guidance to enhance body and soul at times when one feels vulnerable and life seems out of control.  Complementary therapies are used as adjuncts to mainstream care of cancer and other illnesses, not as substitutes. They improve physical and emotional function, and manage stress and symptoms of aging, regardless of health status.  Complementary therapies are rational, evidence-based practices delivered or taught by trained practitioners.  They include: mind-body practices such as meditation and self-hypnosis; massage therapies; nutritional counseling; physical fitness, including programs such as aerobic exercise, Chi Gong, tai chi, yoga and many other practices.
We begin this series with acupuncture, a two-to three-thousand-year-old practice known to relieve difficult, often otherwise untreatable symptoms and effect important improvements in physical function and well-being.......

FDA Approves New Silicone Gel-Filled Breast Implant



FDA Approves New Silicone Gel-Filled Breast Implant:

The U.S. Food and Drug Administration (FDA) has approved a silicone gel-filled breast implant manufactured by Sientra Inc for breast augmentation in women at least 22 years old and breast reconstruction in women of any age.

As a condition of approval, the company is required to conduct post-approval studies to assess long-term safety and effectiveness outcomes as well as the risks of rare disease outcomes.
Silicone gel-filled breast implants are implanted under breast tissue or chest muscle for breast augmentation or reconstruction. They have a silicone outer shell that is filled with silicone gel and come in different sizes.

Breast reconstruction may refer to a primary reconstruction to replace breast tissue that has been removed or revision surgery to correct the result of a primary reconstruction surgery.

The FDA based its approval of Sientra’s implant on 3 years of clinical data from 1,788 participants. Complications and outcomes reflected those found in previous studies of other breast implants and included tightening of the area around the implant (capsular contracture), reoperation, implant removal, an uneven appearance (asymmetry), and infection.
Sientra’s post-approval studies will include:
  • An additional 7 years of follow-up of the 1,788 clinical trial participants in their pre-market study
  • A 10-year study of 4,782 women receiving Sientra silicone gel-filled breast implants to collect information on long-term local complications such as capsular contracture, as well as less common disease outcomes, such as rheumatoid arthritis and breast and lung cancer
  • Five case-control studies that will evaluate the association between Sientra’s silicone gel-filled breast implants and five rare diseases: rare connective tissue disease, neurological disease, brain cancer, cervical/vulvar cancer, and lymphoma.
With the addition of Sientra’s approval, there are now three FDA-approved silicone gel-filled breast implants on the market in the U.S.
Silicone gel implants have generated a fair amount of controversy regarding their safety because of the question as to whether they can trigger certain connective tissue and autoimmune diseases. In 1992, the FDA restricted the use of silicone implants in order to evaluate whether they were indeed associated with autoimmune conditions. Clinical trials have continued and the data continues to indicate that the implants are safe.
It’s important to remember that breast implants are not lifetime devices and long-term monitoring is imperative.
Reference:
FDA approves new silicone gel-filled breast implant [FDA News Release]. U.S. Food and Drug Administration website. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm295437.htm”>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm295437.htm

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA - News



Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA

ROCKVILLE, Md.--()--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin® as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).
“Treatment options are limited for patients who are stricken with ovarian cancer, therefore we look forward to investigating Archexin as a potential combination treatment for this disease.”
The Phase II study will assess the safety and efficacy of Archexin when used in combination with both carboplatin and paclitaxel as a second-line therapy in subjects who are platinum-sensitive following their first relapse. The study will be conducted at multiple centers in the United States, and subjects will be randomized to receive either carboplatin/paclitaxel or carboplatin/paclitaxel/Archexin. Various measures of clinical benefit will be assessed

University of Arizona wins NIH Grant to on Diagnosis of Ovarian Cancer by Confocal Microendoscopy - Optical Coherence Tomography News



University of Arizona wins NIH Grant to on Diagnosis of Ovarian Cancer by Confocal Microendoscopy - Optical Coherence Tomography News

Optical Coherence Tomography News (18 hours ago)

The University of Arizona received a $276,708 2012 NIH grant to study diagnosis of Ovarian Cancer by Confocal Microendoscopy. The principal Investigator is Arthur Gmitro. This grant is part of a multi-year project that started in 2005 and ends in 2014. Below is a summary of the work.
The objective of this research is to further develop and clinically validate a real-time multispectral confocal microendoscope for in vivo diagnosis of ovarian cancer. The confocal microendoscope is a new type of instrument for visualizing tissue at the cellular level and has shown great promise for performing optical biopsy. Confocal microendoscopy has the potential to provide a physician with an immediate evaluation of tissue and to survey a much greater area of tissue, reducing the sampling error of traditional tissue extraction biopsy. A confocal microlaparoscope system was constructed and tested in vivo in humans during the prior funding period. A specific aim of this work is to now validate the system and show that it can be used to detect cancer of the ovary during a laparoscopic procedure. Additional objectives of the work are to expand the use of the instrument to the detection of peritoneal implants of ovarian cancer throughout the abdominal cavity and to develop and test a system capable of imaging inside the fallopian tubes. Further technical development is aimed at improving the confocal imaging performance and adding optical coherence tomography as a complimentary imaging modality. The new instrument will incorporate the two imaging modalities into a single compact probe with seamless and rapid switching between modes of operation. In addition to the technology development and clinical translation, another aim of the project is to develop and test targeted contrast agents that provide safer and more effective in vivo identification of ovarian cancer

paywalled: Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients?



Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients? 

Abstract

Aim:  The effect of systematic retroperitoneal lymphadenectomy (SRL) remains controversial in patients with advanced epithelial ovarian cancer (aEOC) who are optimally debulked.

Conclusion:  Our data suggest that aEOC patients with optimal cytoreduction who underwent SRL did not show a significant improvement in survival irrespective of each histological type.

paywalled: Physical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic Review



Physical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic Review:

Background
Cancer survivors often seek information about how lifestyle factors, such as physical activity, may influence their prognosis. We systematically reviewed studies that examined relationships between physical activity and mortality (cancer-specific and all-cause) and/or cancer biomarkers.

Methods
We identified 45 articles published from January 1950 to August 2011 through MEDLINE database searches that were related to physical activity, cancer survival, and biomarkers potentially relevant to cancer survival. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement to guide this review. Study characteristics, mortality outcomes, and biomarker-relevant and subgroup results were abstracted for each article that met the inclusion criteria (ie, research articles that included participants with a cancer diagnosis, mortality outcomes, and an assessment of physical activity).

Results
There was consistent evidence from 27 observational studies that physical activity is associated with reduced all-cause, breast cancer–specific, and colon cancer–specific mortality. There is currently insufficient evidence regarding the association between physical activity and mortality for survivors of other cancers. Randomized controlled trials of exercise that included biomarker endpoints suggest that exercise may result in beneficial changes in the circulating level of insulin, insulin-related pathways, inflammation, and, possibly, immunity; however, the evidence is still preliminary.

Conclusions
Future research directions identified include the need for more observational studies on additional types of cancer with larger sample sizes; the need to examine whether the association between physical activity and mortality varies by tumor, clinical, or risk factor characteristics; and the need for research on the biological mechanisms involved in the association between physical activity and survival after a cancer diagnosis. Future randomized controlled trials of exercise with biomarker and cancer-specific disease endpoints, such as recurrence, new primary cancers, and cancer-specific mortality in cancer survivors, are warranted.

May 7th: The connection between genes and colon cancer (Lynch Syndrome/FAP) - MD Anderson Cancer Center - audio/ iTunes



The connection between genes and colon cancer - MD Anderson Cancer Center

Cancer Newsline - 05/07/2012


About 20% of colon cancer cases are related to a strong family history of colon cancer. Eduardo Vilar-Sanchez, M.D., Ph.D., Assistant Professor in the Department of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center, focuses his discussion on the main types of genetic colon cancers including hereditary nonpolyposis colorectal cancer syndrome or HNPCC (also called Lynch syndrome) and familial adenomatous polyposis (FAP).

paywalled: Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis



Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.

Abstract

Obesity is associated with poor survival after breast cancer diagnosis in individual studies and meta-analyses. Evidence regarding associations of obesity with breast cancer-specific survival (BCSS) and overall survival (OS) in relation to hormone receptor status, or BCSS in relation to menopausal status has not been evaluated in a previous meta-analysis. ............ These findings led us to conclude that there is no evidence showing that the association of obesity with breast cancer outcome differs by hormone receptor or menopausal status. This has implications for studies of weight loss interventions in the adjuvant BC setting.

Drug Data Shouldn’t Be Secret - NYTimes.com



Drug Data Shouldn’t Be Secret - NYTimes.com

"We should not have to wait for patients to be hurt by the medications they take, as recently happened with the diabetes drug Avandia, before reviewing this wealth of data."

Tuesday, May 08, 2012

Kodak Gallery/Shutterfly FAQ at KODAK Gallery



Kodak Gallery/Shutterfly FAQ at KODAK Gallery

paywalled: Dietary Supplements and Cancer Prevention: Balancing Potential Benefits Against Proven Harms



Dietary Supplements and Cancer Prevention: Balancing Potential Benefits Against Proven Harms

  • Accepted March 12, 2012.

Abstract

Nutritional supplementation is now a multibillion-dollar industry, and about half of all US adults take supplements. Supplement use is fueled in part by the belief that nutritional supplements can ward off chronic disease, including cancer, although several expert committees and organizations have concluded that there is little to no scientific evidence that supplements reduce cancer risk. To the contrary, there is now evidence that high doses of some supplements increase cancer risk. Despite this evidence, marketing claims by the supplement industry continue to imply anticancer benefits. Insufficient government regulation of the marketing of dietary supplement products may continue to result in unsound advice to consumers. Both the scientific community and government regulators need to provide clear guidance to the public about the use of dietary supplements to lower cancer risk.

blog: Supplements: Not mystical anticancer magic [Respectful Insolence]



Supplements: Not mystical anticancer magic [Respectful Insolence]:

It's no secret that over the years I've been very critical of a law passed nearly 20 years ago, commonly referred to as the DSHEA of 1994. The abbreviation DSHEA stands for about as Orwellian a name for a law as I can imagine: the Dietary Supplement Health and Education Act. Of course, as we've pointed out time and time again, the DSHEA is not about health, and it's certainly not about education. Indeed, perhaps my favorite description of this law comes from blog bud and all around awesome internist Dr. Peter Lipson, who refers to it as a "travesty of a mockery of a sham." Rather, it's about allowing supplement manufacturers and promoters of so-called "complementary and alternative medicine" (CAM, with or without a preceding "s," depending on your taste) who do not want pesky things like government laws and regulations to interfere with their selling of pseudoscience to market various compounds as "dietary supplements" with near-impunity. As Harriet Hall once put it so accurately, the DSHEA is "a stealth weapon that allows the sale of unproven medicines just as long as you pretend they are not medicines."
The DSHEA accomplishes this by making a seemingly reasonable distinction between food and medicine and twisting it in such a way that allows manufacturers to label all sorts of botanicals and various other compounds, many of which have substances in them with pharmacological activity, and sell them as "supplements" without prior approval by the FDA before marketing.

medical news: Hypoxia Could Drive Cancer Growth



Hypoxia Could Drive Cancer Growth

"Low oxygen levels in cells may be a primary cause of uncontrollable tumor growth in some cancers, according to a new University of Georgia study. The authors' findings run counter to widely accepted beliefs that genetic mutations are responsible for cancer growth.......

paywalled: Science behind cisplatin-induced nephrotoxicity in humans: A clinical study



Science behind cisplatin-induced nephrotoxicity in humans: A clinical study: Publication year: 2012



Objective To investigate the relationship between serum electrolyte changes and cisplatin induced nephrotoxicity.


Conclusions The present study demonstrates that, acute nephrotoxicity was observed in patients with different types of cancers undergoing cisplatin based chemotherapy due to electrolyte disturbances, when no corrective measures were initiated.

Monday, May 07, 2012

Patients fear being seen as ‘difficult': study - Healthcare business news and research | Modern Healthcare



Patients fear being seen as ‘difficult': study - Healthcare business news and research | Modern Healthcare

Medication Errors Result from Current Medication Reconciliation Practices: It’s Time to Adopt Participatory Reconciliation | Journal of Participatory Medicine



Medication Errors Result from Current Medication Reconciliation Practices: It’s Time to Adopt Participatory Reconciliation | Journal of Participatory Medicine

JCO: A Way Forward on the Medically Appropriate Use of White Cell Growth Factors (hematopoietic colony-stimulating factors (CSFs))



A Way Forward on the Medically Appropriate Use of White Cell Growth Factors

Discussion points:

  • Are Hematopoietic Colony-Stimulating Factors Over- or Underused?
  • Table 1. Comparison of Major Guidelines
  • How Can These Disparate Conclusions Be Reconciled?
  • CSFs for Dose Maintenance in Routine Noncurative Cancer Care
  • CSFs Used to Treat FN or Afebrile Neutropenia
  • What Is the Harm in Using CSFs?
  • Are CSFs a Prudent Use of Societal Resources?
  • Why Do Oncologists Prescribe CSFs if There Is Minimal Evidence for Benefit?
  • How Did We Arrive at Widespread Use Without Clinical Trial Justification?
  • The Way Forward to Evidence-Based Use of CSFs
  • Disclosures/REFERENCES











"There are concrete steps the US oncology community can take to foster more evidence-based care. The Quality Oncology Practice Initiative51 could add overuse as a quality criterion52 and report CSF use in palliative-intent regimens when there is less than a 20% risk of FN. The major guideline groups (European Organisation for Research and Treatment of Cancer,6 National Comprehensive Cancer Network,5 and ASCO4) should endorse dose modification as an equally appropriate and preferred strategy in the absence of proven benefit. "

JCO: Financial Hardship: A Consequence of Survivorship? editorial/link to original paper




editorial:
#1:  Financial Hardship: A Consequence of Survivorship?
Editorial: Financial Hardship: A Consequence of Survivorship?


referenced:
#2:  (paywalled) See accompanying article on page 1608 
 Risk Factors for Financial Hardship in Patients Receiving Adjuvant Chemotherapy for Colon Cancer: A Population-Based Exploratory Analysis





paywalled: How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees (patient safety)




How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees

Purpose

To analyze error disclosure attitudes of radiation oncologists and to correlate error disclosure beliefs with survey-assessed disclosure behavior.

Health News - Targeting ovarian cancer - Dr. Robert Bristow finds disparities in access to the top-quality care that boosts survival



Health News - Targeting ovarian cancer

 Dr. Robert Bristow finds disparities in access to the top-quality care that boosts survival

Not all tumor cells are equal: Huge genetic diversity found in cells shed by tumors



Not all tumor cells are equal: Huge genetic diversity found in cells shed by tumors

Nutrition and physical activity guidelines for cancer survivors - 2012 - CA: A Cancer Journal for Clinicians



Nutrition and physical activity guidelines for cancer survivors - 2012 - CA: A Cancer Journal for Clinicians

Medical News: Breast Imaging (thermography) Study Flunks Clinical Test - in Meeting Coverage



Medical News: Breast Imaging Study Flunks Clinical Test - in Meeting Coverage

Patients Share Of Expensive Specialty Drugs Is Rising - Kaiser Health News (choices: eating vs insurance costs...)



Patients Share Of Expensive Specialty Drugs Is Rising - Kaiser Health News

"....The coinsurance was killing them. "It was a choice between that and eating," says Gary Ryness.
Working with an insurance consultant, they switched from a preferred provider organization to a health maintenance organization that didn't have coinsurance charges for self-injectable drugs such as Avonex. Now, they pay nothing for the drug...."



".....many patients who rely on specialty drugs are coping with very serious, long-term medical conditions. "Consumerism" - encouraging patients to shop wisely for health care - doesn't really apply when such patients need drugs for which there are few or no alternatives, says Stone.
"With people as sick as the patients we're talking about, I don't think they're going to say, 'Is there a less expensive injectable drug I can take?' " she says. "It's a whole different dynamic."
Next week: Some states seek to require parity on oral cancer drug coverage.

April 2011 (latest revision) - Alberta, Canada health services recommendations: RISK REDUCTION AND SURVEILLANCE STRATEGIES FOR INDIVIDUALS AT HIGH GENETIC RISK FOR BREAST AND OVARIAN CANCER





RISK REDUCTION AND SURVEILLANCE STRATEGIES FOR INDIVIDUALS AT HIGH GENETIC RISK FOR BREAST AND OVARIAN CANCER Date Developed: December, 2007 Last Revised: April, 2011

National Guideline Clearinghouse | Epithelial ovarian, fallopian tube, and primary peritoneal cancer - Alberta, Canada



Blogger's Note: note the differences in early stage recommendations per cell type

National Guideline Clearinghouse | Epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Guideline Title

Epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Bibliographic Source(s)
 

Alberta Provincial Gynecologic Oncology Tumour Team. Epithelial ovarian, fallopian tube, and primary peritoneal cancer. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2010 Jul. 19 p. (Clinical practice guideline; no. GYNE-005).  [104 references]



Guideline Status

This is the current release of the guideline.


Scope

Disease/Condition(s)

  • Epithelial ovarian cancer
  • Fallopian tube cancer
  • Primary peritoneal cancer
Guideline Category
Evaluation Management Treatment
Clinical Specialty
Obstetrics and Gynecology Oncology Radiation Oncology Surgery
Intended Users
Physician Assistants Physicians
 
Guideline Objective(s)

To outline management decisions for women with epithelial ovarian, fallopian tube, or primary peritoneal cancer



Key Points
  1. Completely staged, early epithelial ovarian, fallopian tube, and primary peritoneal cancers are highly curable. As such, patients should be referred to a gynecologic oncologist for adequate staging, including sampling of para-aortic and pelvic lymph nodes, infracolic omentectomy, possible appendectomy and biopsy of suspicious peritoneal lesions, in addition to a thorough inspection and palpation of all peritoneal surfaces, and peritoneal washings.
  2. Advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers are best treated with optimal debulking surgery in conjunction with adjuvant therapy. As such, patients should be referred to a gynecologic oncologist  


National Guideline Clearinghouse | Palliative radiotherapy.



Blogger's Note: the document reveals only one indication for ovarian cancer and it has been categorized under urogenital bleeding

National Guideline Clearinghouse | Palliative radiotherapy.

Guideline Objective(s)

To provide recommended palliative radiotherapy strategies for adult patients with advanced cancer

Scope  

Disease/Condition(s)


Advanced cancer with:
  • Brain metastases
  • Malignant epidural spinal cord compression
  • Malignant superior vena cava obstruction
  • Bone metastases
  • Upper aero-digestive tract obstruction, compression, or invasion
  • Malignancy-associated urogenital or gastrointestinal bleeding, or hemoptysis
Guideline Category
Management Treatment
Clinical Specialty
Gastroenterology Neurological Surgery Obstetrics and Gynecology Oncology Pulmonary Medicine Radiation Oncology Urology



Bleeding
Recommendations for Urogenital Bleeding
  1. External beam radiotherapy has been shown to control hematuria in up to 60 percent of patients with advanced bladder cancer; and control rates of 80 percent at six weeks have recently been reported in patients with advanced prostate cancer. In patients with a life expectancy less than six months, external beam radiotherapy treatment with 8 Gy/1 fraction could be considered. Otherwise, a short course multi-fraction schedule could be considered.
  2. In patients with vaginal bleeding who are unsuitable for radical treatment, radiotherapy is effective in resolving bleeding secondary to endometrial or cervical cancer. There is insufficient evidence to recommend an ideal dose and fractionation schedule. Radiotherapy may also be used to control bleeding and palliate pain and mass effect in advanced ovarian cancer.  

paywalled: Clinical implications of pleural effusions in ovarian cancer - Porcel - Respirology - Wiley Online Library



 Blogger's Note: note the use of neoadjuvant therapy in this particular subset of ovarian cancer patients

Clinical implications of pleural effusions in ovarian cancer - Porcel - Respirology

Keywords:

  • malignant pleural effusion;
  • ovarian cancer;
  • thoracoscopy;
  • pleurodesis

ABSTRACT

The pleural cavity constitutes the most frequent extra-abdominal metastatic site in ovarian carcinoma (OC). In patients with OC and pleural effusions, a positive fluid cytology is required for a stage IV diagnosis. Unfortunately, about 30% of malignant pleural effusions exhibit false negative cytological pleural fluid results. In those circumstances, exploratory video-assisted thoracoscopic surgery (VATS) serves as a diagnostic, staging and even therapeutic modality. Maximal (no visible disease) or, at least, optimal (no residual implant greater than 1 cm) cytoreduction should be the primary surgical goal in stage IV OC patients. This is due to residual tumor after cytoreductive surgery being one of the most important factors impacting on survival. Although malignant pleural effusions do not preclude abdominal surgical debulking, excision of gross pleural nodules may be necessary to achieve optimal cytoreduction. VATS quantifies pleural tumor burden and allows for intrathoracic cytoreduction or, if the latter is not feasible, ensures that abdominal surgery is not unnecessarily performed on women in whom gross tumor would still remain in the pleural space afterwards. Taxane-platinum neoadjuvant chemotherapy should be offered to this group. Patients with tumor extension into the pleural space have a median overall survival of 2 years.

Insight: Training immune system to fight cancer comes of age | Reuters



 Blogger's Note: not specific to ovarian cancer

Insight: Training immune system to fight cancer comes of age | Reuters


".....While extending life is the gold standard, most cancer drug trials have been deemed successful if tumors shrink or if a treatment can demonstrate a delay in tumor growth or in worsening of the disease, known as progression-free survival (PFS).
But Provenge and Yervoy have extended survival without necessarily impacting PFS or tumor shrinkage in many cases.
"Overall survival is the accurate indicator. Tumors may look bigger because they are filled with immune cells, so they appear worse," said Wolchok. "We've proposed a new set of response criteria to try to incorporate some of this biology.".......

PLoS ONE: Empty Reviews: A Description and Consideration of Cochrane Systematic Reviews with No Included Studies - your opinions?



Blogger's Note/Opinion: gyn cancers - this topic of discussion should be of interest: Cochrane total gyn cancers reviews = #85; empty reviews = #7; because Cochrane synthesizes and analyses systematic reviews,  often the results are inadequate (for patients/providers) in that studies included are: poor quality; lacking in data or are not randomized clinical trials; we often see this as 'further research is required'; many 'argue' that the value of systematic reviews in gyn cancers are dated (as discussed in this article) but part of this issue is the nature of, in particular, ovarian cancer research itself; the other 'issue' for this blogger is the number of systematic reviews which  continually review reviews; (re: reviews that include Cochrane systematic reviews); there needs to be a streamlining of systematic reviews (randomized clinical trial reviews) nominating or permitting one entity/conglomerate - eg. the philosophy of meaningful use, however, therein lies system wide issues within cancer; observational studies are often not included in the reviews and Cochrane is attempting to address this issue within the parameters of the purpose and philosophy of Cochrane itself, still for quality evidence Cochrane remains the leader; note also that Cochrane has always been one of, if not the leader, in including patients/consumers - your thoughts?

PLoS ONE: Empty Reviews: A Description and Consideration of Cochrane Systematic Reviews with No Included Studies

Introduction  

The Cochrane Library is the largest and perhaps best recognized global collection of health care evidence, currently hosting more than 4,500 systematic reviews in its Cochrane Database of Systematic Reviews (CDSR). However, it has been reported that clinicians find Cochrane reviews of limited relevance to practice decisions. For example, one study found that while Cochrane reviews are highly regarded for their quality, they are used less than other sources for clinical decision-making because of their emphasis on methodology and rigor rather than on clinical relevance [1].
It is not Cochrane's policy to provide guidelines for practice or policy decisions [2]. Instead, it sees itself as the provider of best quality evidence and specifically states that guidelines go “beyond a systematic review and require additional information and informed judgments that are typically the domain of clinical practice guideline developers.”
Systematic reviews that find no studies eligible for inclusion, commonly known as “empty reviews,” may be especially problematic for clinicians and other decision-makers. Little is known about the incidence, prevalence or variation in reporting of such reviews [3]. The little that has been written about them suggests that the reporting of implications for practice may sustain a risk for bias. With no studies meeting criteria for inclusion, these empty reviews may appear to: (1) offer no conclusions, (2) offer conclusions based on referenced excluded studies, (3) offer conclusions based on other evidence, or (4) offer conclusions not based on evidence. Thus, empty reviews may contribute to what appears to be generalized disappointment with The CDSR among some clinicians and policymakers [1], [4]........

Conclusions

The stated purpose of Cochrane reviews is to help healthcare providers, consumers, researchers, and policy makers “make well-informed decisions about health care… by providing a reliable synthesis of the available evidence on a given topic… considering all the evidence on the effect of an intervention” [2]......

Sunday, May 06, 2012

www.ccocr.org - Guest Speakers - 6th Canadian Conference on Ovarian Cancer Research (patients/ advocates need not apply)



Blogger's Note: unlike the annual SGO programme ovarian cancer patient advocates need not apply (not welcome); survivor's course available for a fee

www.ccocr.org - Guest Speakers

Epigenetic modification and cancer: mark or stamp? (BRCA/fallopian tube....)



Epigenetic modification and cancer: mark or stamp?

Abstract

Hypotheses are built upon data, but data require hypotheses before they can be understood. The development of the ‘two-hit’ hypothesis of carcinogenesis was a key event in cancer genetics because it provided a testable model of how tumours develop. In this commentary on ‘Promoter hypermethylation patterns in Fallopian tube epithelium of BRCA1 and BRCA2 germline mutation carriers’ by Bijron et al. published in the February 2012 issue of Endocrine-Related Cancer, the need for new grammar and some new hypotheses in epigenetics is discussed. Meanwhile, data suggesting an important role of epigenetic modification in the cause, progression and treatment of cancer continues to accumulate............

Introduction

In hereditary tumours, the first hit occurs in the germ line, whereas in non-hereditary tumours, the first hit occurs in the cell from which the tumour arises. The second hits are always somatic, and can inactivate the second allele in various different ways. The development of the ‘two-hit’ hypothesis of carcinogenesis was a key event in cancer genetics because it provided a testable model of how tumours develop (Knudson 1971, 1978). Although there have been extensions and revisions to the basic model (Tomlinson et al. 2001), the essential elements of the basic hypothesis remain intact, 40 years on. In the original ‘test case’ of RB-1 mutations in retinoblastoma, these events were physical alterations in the structure of the chromosome or gene (Cavenee et al. 1983), and the perception was such that physical changes put a ‘stamp’ on the tumour that could be detected by examination of genomic DNA.............
continue to read full paper

paywalled: Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.





Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.

Abstract

Pro-inflammatory cytokines, such as interleukin-6 (IL-6), have been implicated in the underlying processes contributing to sleep regulation and fatigue. Despite evidence for sleep difficulties, fatigue, and elevations in IL-6 among women with ovarian cancer, the association between these symptoms and IL-6 has not been investigated. To address this knowledge gap, we examined relationships between sleep disturbance, fatigue, and plasma IL-6 in 136 women with ovarian cancer prior to surgery. These relationships were also examined in 63 of these women who were disease-free and not receiving chemotherapy 1 year post-diagnosis. At both time-points, higher levels of IL-6 were significantly associated with sleep disturbances (p<0.05), controlling for potentially confounding biological and psychosocial covariates. Higher IL-6 was significantly associated with fatigue prior to surgery (p<0.05); however, when sleep disturbance was included in the model, the relationship was no longer significant. IL-6 was not significantly associated with fatigue at 1 year. Changes in sleep over time were significantly associated with percent change in IL-6 from pre-surgery to 1 year, adjusting for covariates (p<0.05). These findings support a direct association of IL-6 with sleep disturbances in this population, whereas the relationship between IL-6 and fatigue prior to surgery may be mediated by poor sleep. As this study is the first to examine cytokine contributions to sleep and fatigue in ovarian cancer, further research is warranted to clarify the role of biological correlates of sleep and fatigue in this population.

The Healthcare Blog: Will Regina Holliday Become Health Care’s Rosa Parks?



Blogger's Note:  the outcome/s of these issues/activities will have international implications with a direct/indirect application to the 99%/1% movements in the recent past
                                   ~~~~~~~~~~~~~~~~~~

Will Regina Holliday Become Health Care’s Rosa Parks?:

By Michael L. Millenson

The protest organized by Regina Holliday over a patient’s right to access their medical information is not quite the same magnitude as agitating for integration in 1950s-era Alabama. Yet there are intriguing similarities between the crusade Rosa Parks launched then and what Holliday is attempting today. Both involve a refusal to accept second-class status and a resolve to push back against entrenched institutions.
Parks’ story is well known. Her refusal to surrender her seat to a white male passenger on a Montgomery city bus in December, 1955, prompted her arrest and a sustained bus boycott by outraged black residents. That boycott’s success propelled a young Martin Luther King, Jr. to the forefront of the fight against segregation. Parks eventually came to be known as the “mother of the modern day civil rights movement.”
Holliday’s protest is seeking media attention – as this is written, it had not taken place – by targeting the American Hospital Association’s annual meeting at a Washington hotel. The rights issue involves how quickly patients are able to see their own electronic medical information after leaving the hospital. The AHA, representing an industry that grew up as “the physician’s workshop,” wants a 30-day grace period to give doctors more time to prepare and review material. Holliday demands immediate access.
What makes this a fight about freedom, and not just fodder for the Federal Register, is its profound potential to affect how each of us takes responsibility for our own health and health care in the digital information age. What is most likely to capture the general public’s interest, however, is the way that general principle finds emotional resonance in Holliday’s personal story.
A widow with two young children, Holliday recalls on her blog how her husband, Fred, died “painfully [from cancer] after suffering for weeks.” She blames inadequate pain management and uncoordinated care due to a chaotic medical record. When they sought access to his electronic medical record, the hospital responded by saying “we must wait 21 days and pay 73 cents per page to see the story of his care. Then they told us we could go home to die.”
Just as Rosa Parks was not a random bus passenger – she and her husband, Raymond, were active members of the NAACP – Holliday is not a random patient protester. An artist, she responded to Fred’s death by becoming a “patients right arts advocate,” producing paintings with titles like “73 Cents,” and “Hubris Hospital” and “Give Us Our Damned Data.”
Also like Parks, Holliday is part of a larger community that shares a similar outrage over being relegated to the back seat, even if in the doctor- and hospital-dominated world of health care, the “back of the bus” is symbolic rather than literal. Her protest drew expressions of support from the National Partnership for Women & Families, the Center for Democracy and Technology and others. But the key to whether this protest is a turning point may lie in a phrase used in a letter supporting immediate access from the Society for Participatory Medicine, to which Holliday belongs. (Disclosure: I’m a Society board member and a friend of Holliday’s, but did not draft the comments.)

The Society wrote: “The overarching principle with respect to patient access to electronic health record data…should be: ‘Nothing about me, without me.’”

That phrase comes from a health care conference held in Salzburg, Austria in the late 1990s. It echoes the slogan, “Nothing about us without us” popularized by disability activists in South Africa and then adopted by activists in this country. It is a powerful statement about equality, engagement and control of one’s own destiny even when those who do not want to share control do so with the best of intentions, whether seeking to help the disabled or trying to implement electronic medical records in hospitals.

The problem, as The Silent World of Doctor and Patient defined it so insightfully more than a quarter-century ago, is that many providers genuinely believe it is their duty to act as “rational agents” on the patient’s behalf without asking the patient’s opinion. In contrast, “nothing about me without me” is the patient’s demand for freedom and, yes, the responsibility that comes with it.

That demand is not unprecedented. I’ve written how new moms were given strict baby feeding schedules by pediatricians until Dr. Benjamin Spock declared that mothers deciding when to feed their babies was “was used by the entire human race until the turn of the century.” How the first American Medical Association code of ethics required patients to obey their doctors, and how it required repeated lawsuits by patients before doctors had to tell patients in clear language the risks as well as benefits of a procedure. And how the AHA, facing the threat of legislation, adopted a Patient Bill of Rights that included such privileges as being told the names of all the doctors treating you.

What distinguishes Holliday’s effort is the power of information access in the digital age. “Give us our damned data” means possessing the raw clinical material that lets us partner with our own doctors or choose other clinicians who better meet our needs. We can go “off the grid,” perhaps “crowdsourcing” questions to others, or we can apply that digitized information to treatment recommendations and outcome prediction algorithms based on the same evidence our doctor uses.

Demanding access to our digitized information immediately, rather than when it is convenient for the doctor and hospital to give it to us, is a stark declaration that it is our health and our lives that are immediately at stake: “Nothing about me without me” from our first cry for food on the day we are born and then every day after.

This dispute may soon be forgotten as a kerfuffle over criteria for “Stage 2 meaningful use” subsidies from the Department of Health and Human Services. But if it can ignite an understanding about what takes for us to be true equals in health and health care decisions, it could be the start of a mass movement that would make Rosa Parks proud.

Michael Millenson is a Highland Park, IL-based consultant, a visiting scholar at the Kellogg School of Management and the author of “Demanding Medical Excellence: Doctors and Accountability in the Information Age.

Survey: doctoral thesis - Personal Health Record System Survey (international survey/anonymous)



Blogger's Note: although many patients/consumers may agree/disagree with the use of the term 'chronic' as it applies to cancer, it is one way to voice your opinions should you choose to do so
                           ~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Survey

PERSONAL HEALTH RECORD SYSTEM SURVEY


The following pages contain an anonymous questionnaire, which we invite you to complete.

This questionnaire was developed as part of a doctoral thesis at HEC Montréal on the following topic: "The role of personal health records in the improvement of healthcare services for individuals with chronic diseases".

Not only will your participation be greatly appreciated, but it may also be beneficial for improving healthcare services for individuals with chronic diseases.

Please answer the questions included in this questionnaire without hesitation, because generally, your first impressions best reflect your true opinions. There is no time limit for completing the questionnaire, although we have estimated that it should take about 30 to 45 minutes.

The information gathered is anonymous and shall remain strictly confidential. It will be used only to advance knowledge and for the dissemination of the overall results at academic or professional forums and thought publications. The information collected for this research project can be utilized in further studies about personal health records and chronic care.

You are completely free to refuse to participate in this project and you may decide to stop answering the questions at any time. If you do not want to answer to a particular question, simply stop answering this questionnaire, which will put an end to your participation to this study. Completing this questionnaire will be considered as your consent to participate in our research project.

If you have any questions about this research, please contact the senior researcher, Dr. Chekli, at the telephone number or email address indicated below.

The research ethics committee of HEC Montréal has determined that the collection of data linked to the present study meets the ethics standards for research involving human subjects. If you have any questions related to ethics, please contact the committee secretary at 1-514-340-7182 or at cer@hec.ca

Thank you very much for your participation.


Mohamed Chekli, MD, MSc eng.
Ph. D. Candidate - Administration
HEC Montréal
1-514-739-2502
mohamed.chekli@hec.ca

Albert Lejeune, PhD
Titular Professor
Université du Québec à Montréal
1-514-987-3000 (#4844)
lejeune.albert@uqam.ca

Francois Bellavance, PhD
Titular Professor
HEC Montréal
1-514-340-6485
francois.bellavance@hec.ca

U.S. Hospital Association (AHA) Fights Digital Data Access for Patients | Center for Democracy & Technology



Hospital Association Fights Digital Data Access for Patients | Center for Democracy & Technology

Forbes: (U.S.) Hospital Association "Declares War" on Patient Empowerment



 Blogger's Note: click on the pdf link for letter from AHA (as below):

"A firestorm has been triggered by the American Hospital Association’s (AHA) 68 page letter (PDF) commenting on the Stage 2 Meaningful Use proposed requirements."
 "Our members are particularly concerned with the proposed objective to provide patients with the ability to view, download and transmit large volumes of protected health information via the Internet (a “patient portal”). The AHA believes that this objective is not feasible as proposed, raises significant security issues, and goes well beyond current technical capacity. We also believe that CMS should not include this objective because the Office of Civil Rights, and not CMS, regulates how health care providers and other covered entities fulfill their obligations under the Health Insurance Portability and Accountability Act (HIPAA), including the obligation to give patients access to their health records. Please see our detailed comments for more
recommendations on changes to specific objectives and measures."

                   ~~~~~~~~~~~~~~~~~~~~~~~~~~


Hospital Association "Declares War" on Patient Empowerment:

A firestorm has been triggered by the American Hospital Association’s (AHA) 68 page letter (PDF) commenting on the Stage 2 Meaningful Use proposed requirements. The reaction has been swift from various individuals and organizations focused on patient rights and empowerment.

Consumer Rights and Patient Empowerment Organizations also weighed in.
  • The Center for Democracy & Technology picked apart the legal “hail mary” that the AHA was using in their response. See Hospital Association Fights Digital Data Access for Patients for more.
  • The Society for Participatory Medicine stated the following. “Patient engagement is the cornerstone of a successful, cost effective, and high-quality health care system,” said Daniel Z. Sands, MD, the Society’s president and a practicing internist. “Those goals cannot be achieved unless we give patients access to their own health information and encourage them to use it.”

Saturday, May 05, 2012

paywalled: Ovarian Low-Grade Serous Carcinoma: A Comprehensive Update



Ovarian Low-Grade Serous Carcinoma: A Comprehe... [Gynecol Oncol. 2012] - PubMed - NCBI

Ovarian Low-Grade Serous Carcinoma: A Comprehensive Update

 Abstract

Ovarian low-grade serous ovarian carcinoma (OvLGSCa) comprises a minority within the heterogeneous group of ovarian carcinomas. Despite biological differences with their high-grade serous counterparts, current treatment guidelines do not distinguish between these two entities. OvLGSCas are characterized by an indolent clinical course. They usually develop from serous tumors of low malignant potential, although they can also arise de novo. When compared with patients with ovarian high grade serous carcinoma (OvHGSCa) patients with OvLGSCa are younger and have better survival outcomes. Current clinical and treatment data available for OvLGSCa come from retrospective studies, suggesting that optimal cytoreductive surgery remains the cornerstone in treatment, whereas chemotherapy has a limited role. Molecular studies have revealed the preponderance of the RAS/RAF/MAPK signalling pathway in the pathogenesis of OvLGSCa, thereby representing an attractive therapeutic target for patients affected by this disease. Improved clinical trial designs and international collaboration are required to optimally address the unmet medical treatment needs of patients affected by this disease.